tiprankstipranks
Advertisement
Advertisement

RPRX Stock Latest News

Royalty Pharma lifts 2026 outlook amid strong cash flows
Company AnnouncementsRoyalty Pharma lifts 2026 outlook amid strong cash flows
2d ago
RPRX
3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy
PremiumMarket News
3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy
3d ago
GMAB
RPRX
Royalty Pharma price target raised to $66 from $59 at Goldman Sachs
PremiumThe Fly
Royalty Pharma price target raised to $66 from $59 at Goldman Sachs
7d ago
RPRX
Royalty Pharma price target raised to $65 from $64 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $65 from $64 at Morgan Stanley
7d ago
RPRX
Royalty Pharma price target raised to $70 from $66 at Citi
PremiumThe Fly
Royalty Pharma price target raised to $70 from $66 at Citi
7d ago
RPRX
Royalty Pharma reports Q2 revenue $647M, consensus $758.88M
PremiumThe FlyRoyalty Pharma reports Q2 revenue $647M, consensus $758.88M
8d ago
RPRX
Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront
Premium
The Fly
Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront
22d ago
AZN
RPRX
Royalty Pharma price target raised to $65 from $50 at TD Cowen
Premium
The Fly
Royalty Pharma price target raised to $65 from $50 at TD Cowen
1M ago
RPRX
Royalty Pharma Shareholders Back Board, Pay and Flexibility
PremiumCompany Announcements
Royalty Pharma Shareholders Back Board, Pay and Flexibility
2M ago
8K
RPRX
Royalty Pharma Secures New $1.8 Billion Credit Facility
PremiumCompany Announcements
Royalty Pharma Secures New $1.8 Billion Credit Facility
3M ago
8K
RPRX
Royalty Pharma price target raised to $64 from $63 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $64 from $63 at Morgan Stanley
3M ago
RPRX
Royalty Pharma price target raised to $58 from $50 at JPMorgan
PremiumThe Fly
Royalty Pharma price target raised to $58 from $50 at JPMorgan
3M ago
RPRX
Royalty Pharma price target raised to $66 from $50 at Citi
PremiumThe FlyRoyalty Pharma price target raised to $66 from $50 at Citi
3M ago
RPRX
Royalty Pharma’s Earnings Call Signals Confident Growth
Premium
Company Announcements
Royalty Pharma’s Earnings Call Signals Confident Growth
3M ago
RPRX
Royalty Pharma price target raised to $57 from $51 at UBS
Premium
The Fly
Royalty Pharma price target raised to $57 from $51 at UBS
4M ago
RPRX
Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside
PremiumRatings
Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside
4M ago
RPRX
Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone
PremiumCompany Announcements
Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone
4M ago
8K
RPRX
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
4M ago
RPRX
Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
PremiumThe Fly
Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
5M ago
JNJ
RPRX
Zymeworks price target raised to $48 from $33 at Evercore ISI
PremiumThe FlyZymeworks price target raised to $48 from $33 at Evercore ISI
5M ago
RPRX
ZYME
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
Premium
The Fly
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
5M ago
RPRX
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
Premium
The Fly
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
5M ago
ONC
JAZZ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >